CHIRON CORP Form 8-K December 10, 2004

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 10, 2004

# **Chiron Corporation**

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	<b>0-12798</b> (Commission File Number)	94-2754624 (IRS Employer Identification No.)
4560 Horton Street, Emeryv (Address of principal executive		<b>94608</b> (Zip Code)
Registrant s telephone number, including area code (510) 655.	-8730	
	N/A	
(Former name or form	mer address, if changed since last report)	
Check the appropriate box below if the Form 8-K filing is inter the following provisions (see General Instruction A.2. below):	nded to simultaneously satisfy the filing o	obligation of the registrant under any of
o Written communications pursuant to Rule 425 under the Sect	urities Act (17 CFR 230.425)	
o Soliciting material pursuant to Rule 14a-12 under the Exchar	nge Act (17 CFR 240.14a-12)	
o Pre-commencement communications pursuant to	Rule 14d-2(b) under the Exchang	e Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to	Rule 13e-4(c) under the Exchange	e Act (17 CFR 240.13e-4(c))

#### **Section 8 Other Events**

Item 8.01.	Other Events
	2004, Chiron Corporation announced via press release that it had received a warning letter from the U.S. Food and Drug DA) in connection with the agency s October 2004 inspection of Chiron s Liverpool facility, which produces FLUVIRIN@ccine.
A copy of Chiron	s press release is attached hereto as Exhibit 99.1.
Item 9.01	Financial Statements and Exhibits
(c)	Exhibits
99.1	Press release issued on December 10, 2004.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHIRON CORPORATION

(Registrant)

Date: December 10, 2004 By: William G. Green

William G. Green

Sr. Vice President; Secretary and Special Counsel to the CEO